PBS Biotech Integrates Rockwell Automation Tech to Streamline Cell Therapy Development
Event summary
- PBS Biotech embedded Rockwell Automation's technology into its MiniPRO™ platform to accelerate cell therapy process development.
- The MiniPRO™ platform features up to 24 independently controlled bioreactors and uses FactoryTalk® software for real-time process control.
- ARMI, a nonprofit advancing the U.S. bioeconomy, was an early adopter of the PBS platform.
- PBS Biotech demonstrated consistent process performance between MiniPRO and its larger-scale Vertical-Wheel® bioreactors.
- The integration aims to reduce risk during scale-up by preserving process knowledge and control from development to commercial manufacturing.
The big picture
The partnership between PBS Biotech and Rockwell Automation addresses critical bottlenecks in cell therapy development, including low-throughput workflows and non-standardized environments. By embedding globally recognized automation technology into its bioreactor systems, PBS Biotech aims to enhance scalability, reproducibility, and regulatory readiness, aligning with broader industry trends toward industrialized cell therapy manufacturing.
What we're watching
- Industry Adoption
- The pace at which other biotech firms adopt the MiniPRO™ platform for cell therapy development.
- Regulatory Readiness
- Whether the standardized automation environment will facilitate smoother regulatory approvals for cell therapy products.
- Scalability
- How effectively the MiniPRO™ platform can integrate into larger manufacturing lines and support commercial-scale production.
Related topics